CClinicalTrials.gg
RecruitingNCT07710573Updated Jul 17, 2026

Brief SEE FAR CBT Intervention Compared With Treatment as Usual for Adults With PTSD

An interventional study of Brief SEE FAR CBT Intervention and Dynamic Psychotherapy Treatment as Usual in Post Traumatic Stress Disorder, sponsored by Community Stress Prevention Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Community Stress Prevention Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical intervention study evaluates a newly developed Brief SEE FAR CBT protocol for adults aged 18 years and older with posttraumatic stress disorder (PTSD), compared with dynamic psychotherapy treatment as usual. Participants in the Brief SEE FAR CBT group will receive 6 focused sessions emphasizing intrusive PTSD symptoms and will then continue to complete the full 12-session SEE FAR CBT protocol. Participants in the control group will receive dynamic psychotherapy as treatment as usual. Psychological outcomes will be assessed using self-report questionnaires at four time points: baseline, after 6 sessions, after 12 sessions, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms, anxiety, depression, perceived stress, resilience, somatic symptoms, sleep quality, and related psychological outcomes over the course of treatment and follow-up.

02

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • PTSD
  • Brief SEE FAR CBT
  • Intervention
03

In context

Stress Disorders, Post-Traumatic

2,239 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 554 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 1,858 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Community Stress Prevention Center is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

Participants must meet all of the following criteria:

  • Age 18 years or older
  • PTSD symptoms, defined as a PCL-5 score of 30-60
  • Hebrew-speaking
  • Able to provide informed consent
  • Willing and able to participate in the assigned psychological intervention and complete study questionnaires at baseline, after 6 sessions, after 12 sessions, and at 3-month follow-up Exclusion Criteria

Participants will be excluded if they meet any of the following criteria:

  • Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes
  • Currently receiving psychotherapy of any type that began less than 3 months prior to enrollment
  • Initiation of psychiatric medication less than 3 months prior to enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Brief SEE FAR CBT Intervention

    Participants in this arm will receive 6 focused sessions of Brief SEE FAR CBT, a newly developed protocol emphasizing intrusive PTSD symptoms. After completing the 6 focused sessions, participants will continue to complete the full 12-session SEE FAR CBT protocol.

    Behavioral: Brief SEE FAR CBT Intervention

  • Experimental
    Dynamic Psychotherapy Treatment as Usual

    Participants in this arm will receive dynamic psychotherapy as treatment as usual, delivered approximately once weekly.

    Behavioral: Dynamic Psychotherapy Treatment as Usual

Interventions

  • BehavioralBrief SEE FAR CBT Intervention

    Brief SEE FAR CBT is a focused trauma-oriented cognitive-behavioral intervention based on the SEE FAR CBT approach. The brief protocol consists of 6 sessions delivered approximately once weekly, with emphasis on intrusive PTSD symptoms. Participants will then continue treatment to complete the full 12-session SEE FAR CBT protocol.

  • BehavioralDynamic Psychotherapy Treatment as Usual

    Participants will receive dynamic psychotherapy as treatment as usual, delivered approximately once weekly. This comparison condition represents the standard psychological treatment provided to participants in this clinical setting.

06

What researchers measure

Primary outcomes

  1. Change in PTSD symptoms

    PTSD Checklist for DSM-5 (PCL-5) PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  2. Change in anxiety symptoms

    Generalized Anxiety Disorder-7 (GAD-7) Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

Secondary outcomes

  1. Change in depressive symptoms

    Patient Health Questionnaire-9 (PHQ-9) Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  2. Change in perceived stress

    Perceived Stress Scale (PSS) Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  3. Change in resilience

    Connor-Davidson Resilience Scale (CD-RISC) esilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  4. Change in somatic symptoms

    Patient Health Questionnaire-15 (PHQ-15) Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  5. Change in trauma-related use of imagination and coping

    FRAME Trauma-related use of imagination and coping will be assessed using the FRAME questionnaire. The FRAME is a 21-item measure of fantastic reality ability, defined as the capacity to use imagination in response to stress or trauma. Items are rated on a 1-7 Likert scale, and mean scores range from 1 to 7, with higher scores indicating greater fantastic reality ability. Change in FRAME score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  6. Change in sleep quality

    Brief Version of the Pittsburgh Sleep Quality Index Sleep quality will be assessed using the brief version of the Pittsburgh Sleep Quality Index. Change in sleep quality score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

  7. Change in PTSD-related functional impairment

    PTSD-related functional impairment will be assessed using the functional impairment section of the Posttraumatic Diagnostic Scale (PDS). This section includes 7 items assessing the extent to which PTSD-related problems interfered with work, relationships, leisure activities, family relationships, sex life, general life satisfaction, and overall functioning during the past two weeks. Items are rated from 0 to 4, and total scores range from 0 to 28, with higher scores indicating greater functional impairment. Change in functional impairment score will be examined across the four study assessment points.

    Time frame: Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

07

Study locations

1 of 1 sites recruiting
  • The Center for Psychological Services Sha'ar Hanegev
    Sha'ar Hanegev, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710573
Lead sponsor
Community Stress Prevention Center
Collaborators
Tel Hai College, The Center for Psychological Services Sha'ar Hanegev
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Meital Mashash, PhD
Contact
meitalm@icspc.org
972-50-2888052
Sivan Raz, PhD
Contact
sivanra@telhai.ac.il
972-54-6634301
Meital Mashash, PhD
principal investigator · Community Stress Prevention Center
Sivan Raz, PhD
principal investigator · Tel Hai College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion